Assessment of bone turnover and bone quality in type 2 diabetic bone disease: Current concepts and future directions

Bone Research

Volumn 4, Issue , 2016, Pages

  Rubin, Mishaela R ^a   Patsch, Janina M ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961656595     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2016.1     Document Type: Article

References (106)

1. IDF Diabetes Atlas 2014. Available at http://www.idf.org/diabete satlas/update-2014.
2. Leslie WD, Rubin MR, Schwartz AV et al. Type 2 diabetes and bone. J Bone Miner Res 2012; 27: 2231-2237.
3. Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32-38.
4. Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
5. Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
6. Leslie WD, Lix LM, Prior HJ et al. Biphasic fracture risk in diabetes: a population-based study. Bone 2007; 40: 1595-1601.
7. de Liefde II, van der Klift M, de Laet CE et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int 2005; 16: 1713-1720.
8. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007; 18: 427-444.
9. Giangregorio LM, Leslie WD, Lix LM et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27: 301-308.
10. Leslie WD, Morin SN, Lix LM et al. Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? Osteoporos Int 2014; 25: 2817-2824.
11. Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-1754.
12. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
13. Dobnig H, Piswanger-Solkner JC, Roth M et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91: 3355-3363.
14. Ardawi MS, Akhbar DH, Alshaikh A et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013; 56: 355-362.
15. Yamamoto M, Yamaguchi T, Nawata K et al. Decreased PTH levels accompanied by low-bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1277-1284.
16. Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the WNT/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 3744-3750.
17. Krakauer JC, McKenna MJ, Buderer NF et al. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775-782.
18. Manavalan JS, Cremers S, Dempster DW et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 3240-3250.
19. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22: 1191-1198.
20. Eghbali-Fatourechi GZ, Modder UI, Charatcharoenwitthaya N et al. Characterization of circulating osteoblast lineage cells in humans. Bone 2007; 40: 1370-1377.
21. Rubin MR, Manavalan JS, Dempster DW et al. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab 2011; 96: 176-186.
22. Ardawi M, Akbar D, Rouzi A et al. Elevated sphingosine 1-phosphate levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Bone Miner Res 2014; 29 Suppl 1. Available at http://www.asbmr.org/education/AbstractDetail?aid=51ef5a65-8072-4369-b2b7-c1381053da59. 11 December 2014.
23. Saito M, Fujii K, Mori Y et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514-1523.
24. Khosravi R, Sodek KL, Faibish M et al. Collagen advanced glycation inhibits its discoidin domain receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Bone 2014; 58: 33-41.
25. Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 2013; 9: 575-583.
26. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 234-241.
27. Gennari L, Merlotti D, Valenti R et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1737-1744.
28. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: 4030-4037.
29. Heilmeier U, Carpenter DR, Patsch JM et al. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int 2015; 26: 1283-1293.
30. Tang SY, Allen MR, Phipps R et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20: 887-894.
31. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013; 36: 1667-1674.
32. Frye EB, Degenhardt TP, Thorpe SR et al. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998; 273: 18714-18719.
33. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 2005; 1043: 567-581.
34. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344 Pt 1: 109-116.
35. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
36. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
37. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 2007; 5: 62-66.
38. Schwartz AV, Garnero P, Hillier TA et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2380-2386.
39. Sanguineti R, Storace D, Monacelli F et al. Pentosidine effects on human osteoblasts in vitro. Ann NY Acad Sci 2008; 1126: 166-172.
40. McCarthy AD, Uemura T, Etcheverry SB et al. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 2004; 36: 840-848.
41. McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 2001; 38: 113-122.
42. Kume S, Kato S, Yamagishi S et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20: 1647-1658.
43. Valcourt U, Merle B, Gineyts E et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007; 282: 5691-5703.
44. Zhang L, Chen B, Tang L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract 2012; 96: 286-293.
45. Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54: 3103-3111.
46. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.
47. Link TM. Osteoporosis imaging: state of the art and advanced imaging. Radiology 2012; 263: 3-17.
48. Schwartz AV, Vittinghoff E, Bauer DC et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305: 2184-2192.
49. Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 2008; 42: 775-787.
50. Harvey NC, Gluer CC, Binkley N et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216-224.
51. Leslie WD, Aubry-Rozier B, Lamy O et al. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013; 98: 602-609.
52. Dhaliwal R, Cibula D, Ghosh C et al. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int 2014; 25: 1969-1973.
53. Kim JH, Choi HJ, Ku EJ et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab 2015; 100: 475-482.
54. Shepherd JA, Schousboe JT, Broy SB et al. Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD. J Clin Densitom 2015; 18: 274-286.
55. Melton LJ 3rd, Riggs BL, Leibson CL et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008; 93: 4804-4809.
56. Patsch JM, Burghardt AJ, Kazakia G et al. Noninvasive imaging of bone microarchitecture. Ann NY Acad Sci 2011; 1240: 77-87.
57. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
58. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Mineral Res 1987; 2: 595-610.
59. Hildebrand T, Ruegsegger P. A new method for the modelindependent assessment of thickness in three-dimensional images. J Microsc 1997; 185: 67-75.
60. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care 1998; 6: 329-337.
61. Manske SL, Zhu Y, Sandino C et al. Human trabecular bone microarchitecture can be assessed independently of density with second generation HR-pQCT. Bone 2015; 79: 213-221.
62. Burghardt AJ, Issever AS, Schwartz AV et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 5045-5055.
63. Shu A, Yin MT, Stein E et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int 2011; 23: 635-641.
64. Patsch JM, Burghardt AJ, Yap SP et al. Increased cortical porosity in type-2 diabetic postmenopausal women with fragility fractures. J Bone Mineral Res 2012; 28: 313-324.
65. Yu EW, Putman MS, Derrico N et al. Defects in cortical microarchitecture among African-American women with type 2 diabetes. Osteoporos Int 2014; 26: 673-679.
66. Petit MA, Paudel ML, Taylor BC et al. Bone mass and strength in older men with type 2 diabetes: the osteoporotic fractures in men study. J Bone Miner Res 2010; 25: 285-291.
67. Majumdar S, Genant HK, Grampp S et al. Correlation of trabecular bone structure with age, bone mineral density, and osteoporotic status: in vivo studies in the distal radius using high resolution magnetic resonance imaging. J Bone Miner Res 1997; 12: 111-118.
68. Majumdar S, Link TM, Augat P et al. Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with fractures of the proximal femur.. Osteoporosis Int 1999; 10: 231-239.
69. Link TM, Majumdar S, Augat P et al. In vivo high resolution MRI of the calcaneus: differences in trabecular structure in osteoporosis patients. J Bone Mineral Res 1998; 13: 1175-1182.
70. Benito M, Gomberg B, Wehrli FW et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003; 88: 1497-1502.
71. Techawiboonwong A, Song HK, Leonard MB et al. Cortical bone water: in vivo quantification with ultrashort echo-time MR imaging. Radiology 2008; 248: 824-833.
72. Benito M, Vasilic B, Wehrli FW et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Mineral Res 2005; 20: 1785-1791.
73. Chesnut CH 3rd, Majumdar S, Newitt DC et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Mineral Res 2005; 20: 1548-1561.
74. Pritchard JM, Giangregorio LM, Atkinson SA et al. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. Arthritis Care Res (Hoboken) 2012; 64: 944.
75. Griffith JF, Yeung DK, Tsang PH et al. Compromised bone marrow perfusion in osteoporosis. J Bone Mineral Res 2008; 23: 1068-1075.
76. Paccou J, Hardouin P, Cotten A et al. The role of bone marrow fat in skeletal health: usefulness and perspectives for clinicians. J Clin Endocrinol Metab 2015; 100: 3613-3621.
77. Patsch JM, Li X, Baum T et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res 2013; 28: 1721-1728.
78. Farina EK, Kiel DP, Roubenoff R et al. Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis study. Am J Clin Nutr 2011; 93: 1142-1151.
79. Jarvinen R, Tuppurainen M, Erkkila AT et al. Associations of dietary polyunsaturated fatty acids with bone mineral density in elderly women. Eur J Clin Nutr 2012; 66: 496-503.
80. Weiss LA, Barrett-Connor E, von Muhlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo study. Am J Clin Nutr 2005; 81: 934-938.
81. Farina EK, Kiel DP, Roubenoff R et al. Dietary intakes of arachidonic acid and alpha-linolenic acid are associated with reduced risk of hip fracture in older adults. J Nutr 2011; 141: 1146-1153.
82. Griel AE, Kris-Etherton PM, Hilpert KF et al. An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutr J 2007; 6: 2.
83. Watkins BA, Li Y, Seifert MF. Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. J Nutr Biochem 2006; 17: 282-289.
84. Coetzer H, Claassen N, van Papendorp DH et al. Calcium transport by isolated brush border and basolateral membrane vesicles: role of essential fatty acid supplementation. Prostaglandins Leukot Essen Fatty Acids 1994; 50: 257-266.
85. Ortiz-Alvarado O, Miyaoka R, Kriedberg C et al. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid in the management of hypercalciuric stone formers. Urology 2012; 79: 282-286.
86. Orchard TS, Cauley JA, Frank GC et al. Fatty acid consumption and risk of fracture in the Women's Health Initiative. Am J Clin Nutr 2010; 92: 1452-1460.
87. Kirkland JL, Tchkonia T, Pirtskhalava T et al. Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol 2002; 37: 757-767.
88. Monickaraj F, Aravind S, Gokulakrishnan K et al. Accelerated aging as evidenced by increased telomere shortening and mitochondrial DNA depletion in patients with type 2 diabetes. Mol Cell Biochem 2012; 365: 343-350.
89. de Heredia FP, Larque E, Portillo MP et al. Age-related changes in fatty acids from different adipose depots in rat and their association with adiposity and insulin. Nutrition 2008; 24: 1013-1022.
90. Morley JE. Diabetes and aging: epidemiologic overview. Clin Geriatr Med 2008; 24: 395-405.
91. Ma YH, Schwartz AV, Sigurdsson S et al. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab 2014; 99: E2584-E2590.
92. Compston JE, Watts NB, Chapurlat R et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med 2011; 124: 1043-1050.
93. Nielson CM, Marshall LM, Adams AL et al. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res 2011; 26: 496-502.
94. Johansson H, Kanis JA, Oden A et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014; 29: 223-233.
95. Sornay-Rendu E, Boutroy S, Vilayphiou N et al. In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study. J Bone Miner Res 2013; 28: 1679-1687.
96. Gerdhem P, Isaksson A, Akesson K et al. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005; 16: 1506-1512.
97. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
98. Bredella MA, Torriani M, Ghomi RH et al. Determinants of bone mineral density in obese premenopausal women. Bone 2011; 48: 748-754.
99. Gilsanz V, Chalfant J, Mo AO et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 2009; 94: 3387-3393.
100. Cohen A, Dempster DW, Recker RR et al. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab 2013; 98: 2562-2572.
101. Amrein K, Amrein S, Drexler C et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012; 97: 148-154.
102. Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. Rev Sci Instrum 2012; 83: 044301.
103. Randall C, Bridges D, Guerri R et al. Applications of a new handheld reference point indentation instrument measuring bone material strength. J Med Dev 2013; 7: 410051-410056.
104. Farr JN, Drake MT, Amin S et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2013; 29: 787-795.
105. Diez-Perez A, Guerri R, Nogues X et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res 2010; 25: 1877-1885.
106. Guerri-Fernandez RC, Nogues X, Quesada Gomez JM et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 2013; 28: 162-168.